Last reviewed 2026-04-23 · How we verify

Menactra TM

Menactra is a meningococcal conjugate vaccine that stimulates the immune system to produce antibodies against serogroups A, C, W, and Y of Neisseria meningitidis.

Menactra is a meningococcal conjugate vaccine that stimulates the immune system to produce antibodies against serogroups A, C, W, and Y of Neisseria meningitidis. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y in individuals 11 years of age and older.

At a glance

Mechanism of action

The vaccine contains polysaccharide capsules from four meningococcal serogroups conjugated to diphtheria toxoid as a carrier protein. This conjugation enhances immunogenicity by promoting T-cell dependent B-cell responses, resulting in robust antibody production and immunological memory against these pathogenic meningococcal strains.

Approved indications

• Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y in individuals 11 years of age and older

Common side effects

• Injection site pain
• Injection site erythema
• Injection site swelling
• Headache
• Fatigue
• Myalgia

Key clinical trials

• Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine Given as One Dose to Healthy Subjects Above 56 Years (PHASE3)
• Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Menactra TM CI brief — competitive landscape report
• Menactra TM updates RSS · CI watch RSS
• GlaxoSmithKline portfolio CI